OBJECTIVES The aims of this study included performing a meta-analysis of the predictive value of late gadolinium enhancement (LGE) cardiac magnetic resonance (CMR) for adverse events and death in hypertrophic cardiomyopathy (HCM).
Cardiac magnetic resonance (CMR), with the advantages of high spatial resolution and tomographic imaging capability, has been applied in diagnosis and prognosis of HCM (6) (7) (8) . Besides routine capacity in cardiac structure and function evaluation, CMR with late gadolinium enhancement (LGE) can identify areas of myocardial fibrosis where life-threatening ventricular tachyarrhythmias originate (9) . However, controversies remain regarding the independent prognostic importance of LGE-CMR in HCM.
Recently, there has been an increasing interest on the prognostic value of LGE for adverse clinical outcomes. A recent meta-analysis by Green et al. (10) showed significant associations between the presence of LGE and cardiovascular mortality, HF death, and all-cause mortality in HCM. However, at the time of Green's meta-analysis (10) , there were only 4 moderately sized studies investigating LGE and adverse events. In the past 3 years, 3 studies (2 updates and 1 new) with more than 2,400 patients on this topic were published (11) (12) (13) ; thus, we have aimed to perform a meta-analysis to identify the predictive value of LGE for SCD, HF death, all-cause mortality, and cardiac mortality. LGE-CMR; included specified endpoints are described in the following section.
Data abstraction and analysis was performed by 2 researchers independently (Z.W. and J.Y.) and reported on standardized forms. All-cause mortality, cardiac death, SCD/aborted SCD, and HF death were assessed as clinical outcome measures. In cases in which endpoints were not specifically reported, study investigators were directly contacted to obtain raw data. Moreover, we extracted the patient characteristics data as described later in the article. In addition, we reclassified patients with implantable cardioverter-defibrillator (ICD) discharge into aborted sudden death according the data provided by Hen et al. (12) .
QUALITY ASSESSMENT. Study quality was evaluated by modified form of the Newcastle-
Ottawa Quality Assessment Scale for Cohort
Studies (14) , in which the quality of the selected trials was determined on the basis of selection of the study groups and ascertainment of the outcome of interest.
DATA ANALYSIS. For the meta-analysis, pooled odds ratios (ORs), hazard ratios (HRs), and 95% confidence intervals (CIs)
were calculated using a fixed effects model according to the Mantel-Haenszel method.
The chosen model was based on the I 2 statistic, which showed a lack of significant heterogeneity for the chosen endpoints.
Publication bias was tested using Begg's funnel plot and Egger's test (15) . A publication bias would be detected if the funnel plot was asymmetric and Egger's test had a p < 0.05.
To determine the relative impact of each study on the pooled results and between-study variability, a "1-study removed" sensitivity analysis was performed. We performed the analyses using 
Weng et al. LGE; p ¼ 0.002) for sudden death events. The study by Hen et al. (12) showed that presence of LGE was also independently associated with cardiovascular LGE; p ¼ 0.007). The extracted outcomes of interest for all these studies are listed in Table 4 .
Cumulative meta-analysis, which includes subsequently overlapped results from Maron et al. (17) and O'Hanlon et al. (18) Two studies in the meta-analysis had much larger sample sizes than the other studies; hence, we performed a 1-study-removed analysis to assess whether the removal of any one study changed the overall results (Online Figure 1) . No change was detected.
Only 3 publications reported risk ratios expressed by quantitative LGE by % left ventricular (LV) mass (11, 13, 19) . These results, supplemented by unpublished data from Chan et al. (11) , are summarized in Table 6 ).
HF DEATH. When the cumulative meta-analysis was repeated for HF death, Figure 4A to 4C shows the undue influence of the study by Ismail et al. (13) LGE and risk of HF death (pooled OR: 7.29; 95% CI:
1.68 to 31.59; p ¼ 0.008). Indeed, up to that point, all 18 HF deaths occurred in patients with LGE (Table 4) . However, Ismail et al. (13) reported 4 of the Table 1 .
Weng et al. LGE; 95% CI: The presence of late gadolinium enhancement by cardiac magnetic resonance predicted all-cause mortality, cardiac death, sudden cardiac death (SCD)/aborted SCD, and heart failure (HF) death. CI ¼ confidence interval. Values are n or n (%).
HF ¼ heart failure;
LGEþ ¼ late gadolinium enhancement positive; LGE-¼ late gadolinium enhancement negative; SCD ¼ sudden cardiac death; other abbreviation as in Table 1 .
was not possible because of the low number of patients with HF death in each study (n # 14). (A) Cumulative analysis using all 7 studies; (B) cumulative analysis using 5 studies. Abbreviation as in Figure 2 . Abbreviations as in Tables 1, 4 , and 5. was significantly associated with cardiac death, HF death, and all-cause mortality in HCM, and showed a trend toward an association with SCD/aborted SCD.
However, there were no data regarding quantitative
LGE.
Since that meta-analysis, 3 large studies (11) (12) (13) have been published. Cumulative analysis using 4 studies. Abbreviation as in Figure 2 . (A) Cumulative analysis using 6 studies; (B) cumulative analysis using 4 studies. Abbreviation as in Figure 2 .
In contrast, our meta-analysis excluded data from Without access to the original data to both studies, it is difficult to ascertain whether LGE has truly independent prognostic value after adjusting for traditional risk factors, including LVEF. We believe the extent of LGE is going to be a far more clinically useful metric than using LGE positive/negative to predict adverse events. That is, the positive predictive value of LGE is expected to be very low because the prevalence of LGE in HCM patients is so high.
These data will need further validation in separate, larger populations with longer follow-up; research is ongoing (23) . More information may also be gleaned from novel CMR techniques such as T1 mapping, which could provide further insights into the role of an abnormal myocardial substrate on adverse events.
Using the current data, we can extrapolate graded levels of risk that may serve as a clinically useful tool to estimate relative risk depending on the amount of
LGE ( Although we were unable to find a significant correlation between LGE and HF deaths, the reason is primarily because of the inclusion of data from Ismail's study (13) , where no significant difference 
